210 related articles for article (PubMed ID: 1334977)
1. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.
Glück R; Mischler R; Brantschen S; Just M; Althaus B; Cryz SJ
J Clin Invest; 1992 Dec; 90(6):2491-5. PubMed ID: 1334977
[TBL] [Abstract][Full Text] [Related]
2. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV).
Glück R; Wälti E
Dev Biol (Basel); 2000; 103():189-97. PubMed ID: 11214236
[TBL] [Abstract][Full Text] [Related]
3. Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system.
Cryz SJ; Glück R
Dev Biol Stand; 1998; 92():219-23. PubMed ID: 9554278
[TBL] [Abstract][Full Text] [Related]
4. Inactivated virosome hepatitis A vaccine.
Loutan L; Bovier P; Althaus B; Glück R
Lancet; 1994 Feb; 343(8893):322-4. PubMed ID: 7905144
[TBL] [Abstract][Full Text] [Related]
5. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines.
Bovier PA; Althaus B; Glueck R; Chippaux A; Loutan L
J Travel Med; 1999 Dec; 6(4):228-33. PubMed ID: 10575170
[TBL] [Abstract][Full Text] [Related]
6. [Immune response to a single dose of a novel kind of hepatitis A vaccine following splenectomy].
Simmen HP; Robustelli L; Althaus B; Glück R; Trentz O; Vogt M
Dtsch Med Wochenschr; 1996 Mar; 121(10):295-8. PubMed ID: 8681712
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial.
Holzer BR; Hatz C; Schmidt-Sissolak D; Glück R; Althaus B; Egger M
Vaccine; 1996 Jul; 14(10):982-6. PubMed ID: 8873392
[TBL] [Abstract][Full Text] [Related]
8. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.
Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W
Isr J Med Sci; 1994; 30(5-6):485-8. PubMed ID: 8034508
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
[TBL] [Abstract][Full Text] [Related]
11. An inactivated hepatitis A viral vaccine of cell culture origin.
Provost PJ; Hughes JV; Miller WJ; Giesa PA; Banker FS; Emini EA
J Med Virol; 1986 May; 19(1):23-31. PubMed ID: 3009703
[TBL] [Abstract][Full Text] [Related]
12. [Immunogenicity of experimentally combined hepatitis A and hepatitis E vaccine at different dosage ratio].
Dong C; Dai X; Meng JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Feb; 23(2):130-3. PubMed ID: 17286906
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a new inactivated hepatitis A vaccine in Thai young adults.
Vimolket T; Theamboonlers A; Dumas R; Milcamps B; Forrat R; Poovorawan Y
Southeast Asian J Trop Med Public Health; 1998 Dec; 29(4):779-85. PubMed ID: 10772564
[TBL] [Abstract][Full Text] [Related]
14. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
[TBL] [Abstract][Full Text] [Related]
15. [Protection of adolescents against hepatitis A].
Puntarić D; Baklaić Z; Ljubicíc M; Vodopija I
Lijec Vjesn; 1996 Oct; 118(10):241-3. PubMed ID: 9132523
[TBL] [Abstract][Full Text] [Related]
16. The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.
Dong C; Dai X; Meng JH
Vaccine; 2007 Feb; 25(9):1662-8. PubMed ID: 17156900
[TBL] [Abstract][Full Text] [Related]
17. Virosomes as carriers for combined vaccines.
Mengiardi B; Berger R; Just M; Glück R
Vaccine; 1995 Oct; 13(14):1306-15. PubMed ID: 8585285
[TBL] [Abstract][Full Text] [Related]
18. Epaxal: a virosomal vaccine to prevent hepatitis A infection.
Bovier PA
Expert Rev Vaccines; 2008 Oct; 7(8):1141-50. PubMed ID: 18844588
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of live attenuated hepatitis A virus vaccine (H2 strain) in humans.
Ran LA; Wang DZ; Duan QY; Yan TY; Liu QL; Luo YG; Yang DZ; Yang DF; Xiao Z; Xie QJ
Chin Med J (Engl); 1993 Aug; 106(8):604-7. PubMed ID: 8222910
[TBL] [Abstract][Full Text] [Related]
20. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration.
Frösner G; Steffen R; Herzog C
J Travel Med; 2009; 16(6):413-9. PubMed ID: 19930383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
